PTC Therapeutics Q1 2024 GAAP EPS $(1.20) Beats $(1.29) Estimate, Sales $210.118M Beat $169.703M Estimate
PTC Therapeutics Q1 2024 GAAP EPS $(1.20) Beats $(1.29) Estimate, Sales $210.118M Beat $169.703M Estimate
PTC Therapeutics 2024年第一季度GAAP每股收益美元（1.20美元）超過預期（1.29美元），銷售額2.10118億美元超過預期的1.6970億美元
PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(1.20) per share which beat the analyst consensus estimate of $(1.29) by 6.98 percent. The company reported quarterly sales of $210.118 million which beat the analyst consensus estimate of $169.703 million by 23.82 percent. This is a 4.66 percent decrease over sales of $220.382 million the same period last year.
PTC Therapeutics（納斯達克股票代碼：PTCT）公佈的季度虧損爲每股1.20美元，比分析師普遍預期的1.29美元（1.29美元）高出6.98％。該公司公佈的季度銷售額爲2.10118億美元，比分析師普遍預期的1.69703億美元高出23.82％。這比去年同期的2.20382億美元銷售額下降了4.66％。